Microsomal triglyceride transfer protein (MTP) is expressed in liver and intestine, where it plays a central role in the assembly and secretion of triglyceride (TG)-rich, apolipoprotein B (apoB)-containing lipoproteins (e.g., liver VLDL and intestinal chylomicrons). MTP catalytic subunit heterodimerizes with protein disulfide isomerase to catalyze the lipidation of the newly synthesized apoB with TG, cholesteryl esters, and phospholipids in the endoplasmic reticulum lumen (reviewed in 1, 2). In the absence of MTP, lipoprotein assembly is blocked, resulting in apoB ubiquitination and its subsequent proteolysis (3, 4). Blocking lipoprotein assembly may lead to hypo/abetalipoproteinemia, hypotriglyceridemia, and hypocholesterolemia at the expense of hepatic steatosis (5-8). On the other hand, overexpression of MTP may result in increased apoB lipidation, its incorporation into plasma apoB-containing lipoproteins, and hyperlipidemia (9). In addition to apoB lipidation and lipoprotein assembly, MTP has recently been implicated in regulating the ability of CD1d-bearing cell types (e.g., hepatocytes, intestinal epithelial cells) to effect CD1d-restricted antigen presentation (10). Thus, abrogation of MTP function may lead to protection from CD1d-mediated hepatitis and/or colitis.
Microsomal triglyceride transfer protein (MTP) is expressed in liver and intestine, where it plays a central role in the assembly and secretion of triglyceride (TG)-rich, apolipoprotein B (apoB)-containing lipoproteins (e.g., liver VLDL and intestinal chylomicrons). MTP catalytic subunit heterodimerizes with protein disulfide isomerase to catalyze the lipidation of the newly synthesized apoB with TG, cholesteryl esters, and phospholipids in the endoplasmic reticulum lumen (reviewed in 1, 2). In the absence of MTP, lipoprotein assembly is blocked, resulting in apoB ubiquitination and its subsequent proteolysis (3, 4) . Blocking lipoprotein assembly may lead to hypo/abetalipoproteinemia, hypotriglyceridemia, and hypocholesterolemia at the expense of hepatic steatosis (5) (6) (7) (8) . On the other hand, overexpression of MTP may result in increased apoB lipidation, its incorporation into plasma apoB-containing lipoproteins, and hyperlipidemia (9) . In addition to apoB lipidation and lipoprotein assembly, MTP has recently been implicated in regulating the ability of CD1d-bearing cell types (e.g., hepatocytes, intestinal epithelial cells) to effect CD1d-restricted antigen presentation (10) . Thus, abrogation of MTP function may lead to protection from CD1d-mediated hepatitis and/or colitis.
The 5 Ј -flanking 200 bp of the MTP gene promoter are highly conserved in human and hamster (11) . The human MTP (hMTP) promoter consists of consensus sequences for sterol regulatory element binding protein (SREBP; Ϫ 124/ Ϫ 116), insulin ( Ϫ 122/ Ϫ 111), activator protein 1 (AP-1; Ϫ 109/ Ϫ 104), and hepatocyte nuclear factor-1 ␣ (HNF-1 ␣ ; Ϫ 103/ Ϫ 98). Transfection analysis has indicated that the hMTP promoter activity was reduced by more than 95% by deleting the promoter to Ϫ 87 bp or by mutating its HNF-1 ␣ or AP-1 elements (11) . The hMTP promoter is further controlled by more distal promoter elements. Of particular interest is the G493T mutation, which results in higher promoter activity with a concomitant increase in the production of postprandial chylomicrons and VLDL (12, 13) .
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The expression of MTP is regulated by dietary cholesterol and fatty acids. Thus, sterol depletion results in a decrease (14, 15) , whereas saturated fat (e.g., hydrogenated coconut oil, tripalmitin, or trimyristin) leads to an increase (16, 17) , in MTP expression and its protein content. MTP suppression by cholesterol depletion is mediated by binding of SREBP to the sterol response element in the MTP promoter (15) . Modes of activation of MTP expression by saturated fatty acids remain to be investigated.
HNF-4 ␣ is a member of the superfamily of nuclear receptors. Mammalian HNF-4 ␣ is expressed in liver, kidney, intestine, and pancreas, where it controls the expression of nuclear receptors (e.g., HNF-1 ␣ ), enzymes, and proteins involved in lipoprotein and lipid metabolism, carbohydrate metabolism, blood coagulation, and others (reviewed in 18). Transcriptional activation by HNF-4 ␣ is mediated by its binding as a homodimer to direct repeat 1 (DR1) promoter sequences of target genes. HNF-4 ␣ binding to DR1 sequences may be competed out by peroxisome proliferator-activated receptor/retinoid X receptor (PPAR/RXR), retinoic acid receptor/RXR, and chicken ovalbumin upstream promoter transcription factor I or II (COUP-TFI or COUP-TFII) (19) (20) (21) (22) . Transcriptional modulation by HNF-4 ␣ may further be mediated by its physical interaction with other transcription factors (e.g., HNF-1 ␣ , COUP) (23, 24) .
Until recently, HNF-4 ␣ was considered to be an orphan nuclear receptor. However, truncated HNF-4 ␣ ligand binding domain (LBD) recombinants have recently been reported to consist of bound long-chain fatty acids (25) . Furthermore, various long-chain saturated or unsaturated fatty acyl-CoA thioesters longer than C12 have now been reported by us to specifically bind to the full-length HNF-4 ␣ or its LBD recombinants with K d values in the 2.0-4.0 nM range (26, 27) . Also, the transcriptional activity of HNF-4 ␣ in transfected cells is affected by added fatty acids as a function of their chain length, unsaturation, or extent of substitution (26, 28) . Thus, saturated fatty acids of C14-C16 activate HNF-4 ␣ transcriptional activity, whereas its activity is robustly suppressed by (n-3)PUFAs or hypolipidemic xenobiotic amphipathic carboxylates [e.g., fibrates, Methyl-substituted dicarboxylic acid (Medica) analogs] (26, 29) .
Selective activation of MTP expression by saturated fatty acids (16, 17) and suppression of TG-rich lipoprotein production by hypolipidemic xenobiotic amphipathic carboxylates (30, 31) , together with the capacity of these effectors to activate or inhibit HNF-4 ␣ transcriptional activity, respectively (26) (27) (28) (29) , prompted us to analyze the putative role played by HNF-4 ␣ in directly modulating the transcription of the human MTP gene.
EXPERIMENTAL PROCEDURES hMTP promoter constructs
The ( Ϫ 611/ ϩ 87)hMTP(WT) wild-type promoter fragment was generated by PCR from genomic DNA. Forward and reverse primers were 5 Ј -TCCCCCGGGTGTGCTAATGACAGACAATGC-3 Ј and 5 Ј -TCCCCCGGGTATTGACCAGCAATCCTCAAC-3 Ј , respectively. After digestion with Sma I, the resulting fragment was cloned into a promoterless CAT reporter vector (32) . The ( Ϫ 74/ ϩ 87) hMTP(WT) wild-type promoter fragment was generated by restriction of the ( Ϫ 611/ ϩ 87)hMTP Ava II site, followed by filling the overhang using the Klenow fragment of DNA polymerase I. The resulting 161 bp fragment was cloned into the Sma I site of the promoterless CAT reporter vector. ( Ϫ 611/ ϩ 87)hMTP(P-mut)-CAT and ( Ϫ 74/ ϩ 87)hMTP(P-mut)-CAT were generated by in vitro mutagenesis (QuikChange Site-Directed Mutagenesis kit; Stratagene) of ( Ϫ 611/ ϩ 87)hMTP(WT)-CAT and ( Ϫ 74/ ϩ 87) hMTP(WT)-CAT, respectively. The mutated P-DR1 (P-mut) primers consisted of 5 Ј -GGAGTTTGGAGTCTGTGCTTTCCCCAAA-GATAAAC-3 Ј (forward) and 5 Ј -GTTTATCTTTGGGGAAAGCA-CAGACTCCAAACTCC-3 Ј (reverse) sequences. ( Ϫ 611/ ϩ 87)hMTP-(D-mut)-CAT was generated by in vitro mutagenesis of ( Ϫ 611/ ϩ 87)hMTP-(WT)-CAT. The mutated D-DR1 (D-mut) primers consisted of 5 Ј -GTGAGCCCTTCAGTGTTGTTACCTCCTGATT-TTGGAG-3 Ј (forward) and 5 Ј -CTCCAAAATCAGGAGGTAACAA-CACTGAAGGGCTCAC-3 Ј (reverse) sequences. Oligonucleotide primers for PCR were prepared by IDT (Coralville, IA). All promoter constructs were confirmed by sequencing.
Expression plasmids
pSG5-HNF-4 ␣ wild-type and pSG5-HNF-4 ␣ (C179W) were constructed as previously described (28, 33) . pSG5-HNF-4 ␣ (Y6D, Y14D,F19D) was constructed in three steps using the Quick Change Site-Directed Mutagenesis kit. The following primers were used: Y6D sense (5 Ј -CATGGACATGGCTGACGACAGTGCTGCCTTGG-3 Ј ) and antisense; Y14D sense (5 Ј -GCCTTGGACCCAGCCGACA-CCACCCTGGAGTTTG-3 Ј ) and antisense; and F19D sense (5 Ј -CACCACCCTGGAGGATGAAAATGTGCAGGTG-3 Ј ) and antisense. Mutant constructs were verified by sequencing. pcDNA3-DN-HNF-4 ␣ was constructed by cloning the HNF-4 ␣ gene fragment encoding amino acids 112-455, prepared by PCR, into the pcDNA3 Kpn I /Eco RV sites. The pSG5-mPPAR ␣ expression plasmid was from S. Green (34) . pSG5-COUP-TFI and pSG5-COUP-TFII were from Y. Bergman (35) .
Cell cultures and transfection assays
HepG2 cells grown in MEM-EAGLE medium containing 10% fetal calf serum were transfected for 6 h by calcium phosphate precipitation with 5.0 g of hMTP promoter-CAT reporter plasmids, washed, and further incubated for 24-40 h. HeLa cells grown in DMEM containing 10% fetal calf serum were transfected overnight by calcium phosphate precipitation with 5.0 g of hMTP promoter-CAT reporter plasmids, followed by glycerol shock and further incubation for 24 h. When cotransfecting expression vectors, the total amount of DNA was kept constant by supplementing with the pSG5 or pcDNA3 empty vector. CAT values were normalized to ␤ -galactosidase activity.
Chromatin immunoprecipitation analysis
HepG2 cells plated in 100 mm dishes were fixed with 1% formaldehyde, neutralized with glycine for 5 min to a final concentration of 125 mM, rinsed with PBS, and harvested. The cell pellet was rinsed once in TBS (150 mM NaCl, 20 mM Tris-HCl, pH 7.6), frozen in liquid nitrogen, and kept at Ϫ 70 Њ C. The cell pellet was sonicated to yield DNA fragments of ‫ف‬ 700 bp on average, immunoprecipitated with 3 g of anti-HNF-4 ␣ antibody (Santa Cruz Sc-8987) or with control IgG, and the precipitated DNA was prepared according to Chakravarty et al. (36) . The purified DNA isolated by immunoprecipitation was analyzed by PCR using the forward (5 Ј -CTGGTTTGGTTTAGCTCTC-3 Ј ) and reverse (5 Ј -GACCCTCTTCAGAACCTG-3 Ј ) primers for the ( Ϫ 211/ Ϫ 1) hMTP gene promoter, the forward (5 Ј -CAGCCTGTTTGGGAAby guest, on October 29, 2017 www.jlr.org Downloaded from CTCAG-3 Ј ) and reverse (5 Ј -CATACCACCACCAATCACTTC-3 Ј ) primers for the ( Ϫ 689/ Ϫ 482)hMTP gene promoter, and the forward (5 Ј -GCCAACGCCAAAACTCTCCCTCC-3 Ј ) and reverse (5 Ј -CGAGCCATAAAAGGCAACTTTCG-3 Ј ) primers for the ␤ -actin gene promoter. The amplified 32 P-labeled DNA fragments were separated by electrophoresis using 8% acrylamide gel and analyzed with a PhosphorImager.
Cell infection
The parent plasmids pAdEasy-1 and pAdTrack-cytomegalic virus (CMV) were provided by H. Giladi (Gene Therapy Department, Hadassah Hospital, Jerusalem, Israel). Recombinant adenoviruses were prepared as described by He et al. (37) . Ad-HNF-4 ␣ was constructed by cloning a Bsm I /Sph I fragment of pSG5-HNF-4 ␣ encoding amino acids 1-455 into pAdTrack-CMV followed by recombination with pAdEasy-1 to yield an adenovirus harboring the HNF-4 ␣ and green fluorescent protein (GFP) cDNAs in tandem, downstream of separate CMV promoters. Viruses were propagated in 293 cells. Hep3B cells were infected with Ad-virus (vector backbone containing the GFP cDNA but lacking HNF-4 ␣ cDNA) or Ad-HNF-4 ␣ as indicated and cultured for 48 h. Infection efficacy amounted to 70-100%.
hMTP and human apoA-I mRNA levels Total RNA was prepared using the EZ-RNA kit (Biological Industries, Beit Haemek, Israel). hMTP mRNA levels were determined by semiquantitative RT-PCR. First-strand cDNA used as template was synthesized by reverse transcription using oligo(dT) as primer and Moloney murine leukemia virus RT (Invitrogen). PCR was performed in a total volume of 25 l containing 1 l of the RT reaction as template, 10 mM Tris-HCl (pH 9 at 25 Њ C), 50 mM KCl, 0.1% Triton X-100, 1. Human apoA-I was determined by Northern blot analysis. ApoA-I mRNA was probed using the human apoA-I cDNA.
Gel electrophoretic mobility shift assay
Double-stranded radiolabeled oligonucleotides were prepared by the Klenow fragment of DNA polymerase I and [ 32 P]dCTP using the following double-stranded oligonucleotides,
(Ϫ96/Ϫ84)hMTP: 5Ј-ACGTTTAATCATTAATAGTGAGCCCTTCAGTGAA ATTAGTAATTATCACTCGGGAAGTCACTT.
Nuclear extracts were prepared from COS7 cells with or without HNF-4␣ overexpression and from HepG2 cells. Harvested cells were suspended in hypotonic buffer (10 mM Hepes, pH 7.9, 10% glycerol, 1.5 mM MgCl 2 , 10 mM KCl, 0.2 mM phenylmethylsulfonyl fluoride, 0.5 mM DTT, 10 g/ml aprotinin, and 2 g/ml leupeptin), incubated for 10 min on ice, homogenized, and centrifuged at 4,000 rpm for 15 min. The pellet was resuspended in low-salt buffer (20 mM Hepes, pH 7.9, 25% glycerol, 1.5 mM MgCl 2 , 20 mM KCl, 0.2 mM EDTA, 0.2 mM phenylmethylsulfonyl fluoride, 0.5 mM DTT, 10 g/ml aprotinin, and 2 g/ml leupeptin) followed by dropwise addition of high-salt buffer (20 mM Hepes, pH 7.9, 25% glycerol, 1.5 mM MgCl 2 , 1.2 M KCl, 0.2 mM EDTA, 0.2 mM phenylmethylsulfonyl fluoride, 0.5 mM DTT, 10 g/ml aprotinin, and 2 g/ml leupeptin) (0.5ϫ packed nuclear volume), incubated for 30 min on ice with continuous mixing, and centrifuged at 25,000 g. The supernatant was stored at Ϫ70ЊC.
Nuclear extracts were incubated with or without added unlabeled competitor oligonucleotides or anti-HNF-4␣ antiserum as indicated in a total volume of 20 l containing 10 mM Hepes, pH 7.8, 50 mM KCl, 2.5 mM MgCl 2 , 10% glycerol, 1 mM DTT, and 3.0 g of poly(dI-dC). After 30 min of incubation on ice, the radiolabeled oligonucleotide was added, and the reaction mixture was further incubated for 15 min at room temperature. Protein-DNA complexes were separated with a 5% polyacrylamide gel and analyzed with a PhosphorImager.
RESULTS

Transactivation of the hMTP gene promoter by HNF-4␣
Modulation of hMTP gene expression by HNF-4␣ was evaluated in Hep3B cells infected with Ad-HNF-4␣ (38) compared with Ad-virus. Expression of the HNF-4␣-responsive gene apoA-I served as positive control. Ad-HNF-4␣ infection resulted in 60% and 70% increases in human apoA-I and MTP mRNA levels, respectively ( Fig. 1) , indicating that expression of the endogenous hMTP gene was modulated by added HNF-4␣.
Transactivation of the hMTP gene promoter by HNF-4␣ was evaluated in HepG2 cells transfected with a CAT reporter plasmid promoted by the 5Ј-flanking Ϫ611 bp sequence of the hMTP gene promoter [(Ϫ611/ϩ87)hMTP-CAT]. Cotransfection of the reporter plasmid together with an expression vector for HNF-4␣ resulted in a 5-fold increase in hMTP promoter activity (Fig. 2) , indicating that the 5Ј-flanking Ϫ611 bp sequence of the hMTP gene promoter may account for the transcriptional regulation of the hMTP gene by transfected HNF-4␣. Transactivation of the hMTP gene promoter by the endogenous HNF-4␣ was evaluated by transfecting HepG2 cells with dominant negative HNF-4␣ (DN-HNF-4␣) that lacks the DNA binding domain, thus forming nonfunctional homodimers with the endogenous HNF-4␣ (38) . Cotransfection of the (Ϫ611/ϩ87)hMTP-CAT reporter plasmid together with an expression vector for DN-HNF-4␣ resulted in a 60% decrease in hMTP promoter activity (Fig. 2) , indicating that endogenous HNF-4␣ may limit hMTP transcription in transfection assays.
HNF-4␣ interaction in vivo with the hMTP gene promoter was evaluated by chromatin immunoprecipitation (CHIP) analysis of HepG2 DNA using anti-HNF-4␣ antiserum. Endogenous HNF-4␣ was found to associate with the (Ϫ211/Ϫ1)hMTP 5Ј-flanking promoter sequence but not with the (Ϫ689/Ϫ482)hMTP promoter sequence or the ␤-actin gene promoter (Fig. 3) , indicating that the endogenous HNF-4␣ specifically interacted in vivo with the hMTP proximal promoter. These results corroborate and extend the recently reported association of HNF-4␣ with the (Ϫ700/ϩ200)hMTP promoter (39) .
DR1 elements of the proximal hMTP gene promoter
The (Ϫ96/Ϫ84)hMTP promoter sequence GTGAGC-CCTTCAG has previously been reported by Hagan et al. (11) to serve as a response element for HNF-4␣, based on its apparent homology with the HNF-4␣ response element in the apoB gene promoter (40) . Two other putative DR1 sequences that may serve as response elements for HNF-4␣ in the (Ϫ611/ϩ87)hMTP promoter context were indicated by MatInspector analysis: a distal (Ϫ83/Ϫ70)hMTP DR1 element (D-DR1) consisting of TGAACTTAGGTCCT and a proximal (Ϫ50/Ϫ38)hMTP DR1 element (P-DR1) consisting of TGACCTTTCCCCA.
HNF-4␣ binding to DR1 elements of hMTP was evaluated by gel mobility shift assay using the wild-type P-DR1 and D-DR1 oligonucleotides as well as their respective P-mut and D-mut mutants (Fig. 4A) . Nuclear extract of COS7 cells overexpressing HNF-4␣ bound to labeled P-DR1, and binding was effectively competed out by nonlabeled P-DR1 (Fig. 4B ) but not by P-mut (data not shown). Similarly, HNF-4␣ of HepG2 nuclear extract bound to P-DR1, and the respective band was supershifted by anti-HNF-4␣ antiserum (Fig. 4C) . HNF-4␣ binding to P-DR1 was specific, being effectively competed out by nonlabeled P-DR1 or by the nonlabeled HNF-4␣/C3P element of the apoC-III gene promoter (20, 33) , but less by nonlabeled P-mut (Fig. 4C) . Nuclear extract of COS7 cells overexpressing HNF-4␣ bound as well to labeled D-DR1, and binding was effectively competed out by nonlabeled D-DR1 (Fig.   4D ). In contrast to P-DR1 and D-DR1, nuclear extract of COS7 cells overexpressing HNF-4␣ did not bind to the (Ϫ96/Ϫ84)hMTP promoter sequence previously reported as a putative response element for HNF-4␣ (11) (Fig. 4D) . Similarly, HepG2 nuclear extract did bind to D-DR1, and the respective band was supershifted by anti-HNF-4␣ antiserum (Fig. 4E) . HNF-4␣ binding to D-DR1 was specific, being competed out by nonlabeled D-DR1 or by nonlabeled C3P but not by the nonlabeled (Ϫ96/Ϫ84) hMTP promoter sequence or by D-mut (Fig. 4E) . Also, in agreement with the inefficacy of the (Ϫ96/Ϫ84)hMTP promoter sequence to compete out HNF-4␣ binding to D-DR1, HNF-4␣ did not bind to the labeled (Ϫ96/Ϫ84) hMTP element, as verified by the lack of supershift by anti-HNF-4␣ antiserum and by the lack of competition by nonlabeled D-DR1 or C3P (Fig. 4E) . Hence, the (Ϫ611/ ϩ87)hMTP promoter consists of two binding sites for HNF-4␣, D-DR1 and P-DR1, whereas the previously reported (Ϫ96/Ϫ84) hMTP sequence does not serve as a response element for HNF-4␣.
P-DR1 and D-DR1 as response elements for HNF-4␣
The functional role of P-DR1 and D-DR1 in the context of the hMTP gene promoter was evaluated in HepG2 cells transfected with a CAT reporter plasmid promoted by the (Ϫ611/ ϩ87)hMTP(WT) wild-type promoter, the (Ϫ611/ϩ87) hMTP(P-mut) promoter consisting of the P-mut sequence, the (Ϫ611/ϩ87)hMTP(D-mut) promoter consisting of the D-mut sequence, or the (Ϫ611/ϩ87)hMTP(P-mut/ D-mut) promoter consisting of the P-mut and D-mut sequences replacing the wild-type P-DR1 and D-DR1 se- Fig. 5 . Transactivation of wild-type and mutated hMTP promoter by HNF-4␣. A: hMTP reporter plasmids. B: HepG2 cells were cotransfected with wild-type (WT), P-mut, D-mut, or P-mut/D-mut (Ϫ611/ϩ87)hMTP-CAT or with wild-type or P-mut (Ϫ74/ϩ87)hMTP-CAT reporter plasmids as indicated. CAT activities normalized to ␤-galactosidase are presented as fold induction relative to CAT activity of cells transfected with wild-type (Ϫ611/ϩ87)hMTP-CAT taken as 1.0. Values shown are means Ϯ SEM for four independent experiments. * Differs significantly from CAT activity in cells transfected with wild-type (Ϫ611/ϩ87)hMTP-CAT (P Ͻ 0.05); # differs significantly from CAT activity in cells transfected with wild-type (Ϫ74/ϩ87)hMTP-CAT (P Ͻ 0.05). C: HeLa cells were cotransfected with wild-type, P-mut, D-mut, or P-mut/D-mut (Ϫ611/ϩ87)hMTP CAT or with wild-type (Ϫ74/ϩ87)hMTP-CAT reporter plasmids as indicated and expression vectors for HNF-4␣ (0.05 g) or the empty pSG5 vector as described in Experimental Procedures. CAT activities normalized to ␤-galactosidase are presented as fold induction relative to CAT activities of cells transfected with pSG5 taken as 1.0. Values shown are means Ϯ SEM for three independent experiments. * Differs significantly from the pSG5 value (P Ͻ 0.05).
by guest, on October 29, 2017 www.jlr.org Downloaded from quences, respectively. These studies were complemented by evaluating the promoter activities of the truncated (Ϫ74/ϩ87)hMTP-CAT reporter plasmid and of its (Ϫ74/ ϩ87)hMTP(P-mut)-CAT mutant, consisting of the P-DR1 response element or its respective mutant in the context of (Ϫ74/ϩ87)hMTP promoter, devoid of D-DR1 (Fig. 5A) .
The promoter activity of the (Ϫ611/ϩ87)hMTP-CAT reporter plasmid mutated either in its P-DR1 or D-DR1 element was reduced by 75-80% compared with wild-type (Ϫ611/ϩ87)hMTP(WT)-CAT (Fig. 5B) , thus indicating that each of the two elements was required for the wildtype promoter activity in HepG2 cells. Also, the (Ϫ611/ ϩ87)hMTP promoter activity was essentially eliminated by mutating both DR1 elements (Fig. 5B) . The function of the P-DR1 element was further realized in the context of the truncated (Ϫ74/ϩ87)hMTP promoter. In agreement with Hagan et al. (11) , the promoter activity of (Ϫ74/ ϩ87)hMTP was decreased by 95% compared with (Ϫ611/ ϩ87)hMTP as a result of the deletion of the AP-1 (Ϫ109/ Ϫ104) and HNF-1␣ (Ϫ103/Ϫ98) elements. The residual activity of the truncated (Ϫ74/ϩ87)hMTP promoter, however, was essentially eliminated in the (Ϫ74/ϩ87)hMTP (P-mut) promoter context (Fig. 5B) . Hence, the hMTP promoter activity was robustly affected in HepG2 cells by both its P-DR1 and D-DR1 elements.
The contribution made by P-DR1 and D-DR1 to the full promoter activity of (Ϫ611/ϩ87)hMTP in response to transfected HNF-4␣ was evaluated in HeLa cells devoid of endogenous HNF-4␣ that do not express MTP (11) . Cotransfection of (Ϫ611/ϩ87)hMTP with an expression plasmid for HNF-4␣ resulted in a 70-fold increase in the promoter activity. The HNF-4␣-dependent promoter activity of (Ϫ611/ϩ87)hMTP mutated either in P-DR1 or D-DR1 was decreased by 90% and 80%, respectively, compared with the wild-type promoter, whereas the doubly mutated promoter was essentially not activated by HNF-4␣ (Fig.  5C) . Also, the HNF-4␣-dependent promoter activity of the truncated (Ϫ74/ϩ87)hMTP-CAT reporter was 10-fold decreased compared with (Ϫ611/ϩ87)hMTP-CAT (Fig.  5C) . Hence, each of the two elements was required for full transactivation of the (Ϫ611/ϩ87)hMTP promoter by HNF-4␣.
HNF-4␣/HNF-1␣ synergism
In addition to the HNF-4␣ response elements P-DR1 and D-DR1, the (Ϫ611/ϩ87)hMTP gene promoter consists of a critical (Ϫ103/Ϫ98)HNF-1␣ response element necessary for the promoter activity, as previously verified by the 95% decrease in the activity of the hMTP promoter mutated in its HNF-1␣ element (11) . HNF-4␣ and HNF-1␣ have previously been reported to physically interact (23) and to transcriptionally antagonize (23) or synergize (41) each other, thus prompting our interest in studying their putative interaction in the context of the hMTP gene promoter.
Putative HNF-4␣/HNF-1␣ interactions in the context of the hMTP gene promoter and the contribution made by P-DR1 and D-DR1 to that interaction were verified in HeLa cells cotransfected with hMTP-promoted CAT reporter plasmids together with expression vectors for HNF-4␣ and/or HNF-1␣ (Fig. 6) . The (Ϫ611/ϩ87)hMTP(WT) promoter was 64-fold transactivated by HNF-4␣ in the absence of transfected HNF-1␣ but was marginally transactivated by HNF-1␣ in the absence of transfected HNF-4␣ (Fig. 6A) . However, the wild-type promoter was robustly activated (1,250-fold) by cotransfecting HNF-4␣ and HNF-1␣ (Fig. 6A) , indicating that the wild-type hMTP promoter activity was limited by each and could be synergistically activated by HNF-4␣ and HNF-1␣. The synergistic interaction between HNF-4␣ and HNF-1␣ was independently maintained by each of the two HNF-4␣ response elements, P-DR1 and D-DR1 (Fig. 6B, C) , but was essentially eliminated in the context of the doubly mutated (Ϫ611/ ϩ87)hMTP(P-mut/D-mut) (Fig. 6D) . Hence, HNF-4␣ docking to at least one of the two HNF-4␣ response elements of the hMTP promoter was required and sufficient for the HNF-4␣/HNF-1␣ synergistic interaction. Furthermore, the HNF-4␣/HNF-1␣ synergistic interaction maintained by HNF-4␣ docking to P-DR1 required additional promoter elements, as verified by the lack of activation of the truncated (Ϫ74/ϩ87)hMTP promoter by HNF-1␣ in the absence or presence of added HNF-4␣ (data not shown). Docking of HNF-1␣ to its response element in the context of HNF-4␣/ HNF-1␣ synergism remains to be verified.
Transcriptional regulation of hMTP by HNF-4␣ mutants
The requirement for functional ligand-dependent domains of HNF-4␣ for hMTP transactivation by HNF-4␣ and for its synergism with HNF-1␣ was evaluated in HeLa cells cotransfected with wild-type HNF-4␣ or with the HNF-4␣(C179W) mutant, previously shown to be defective in acyl-CoA binding and in recruiting HNF-4␣ transcriptional coactivators and to lack ligand-dependent transcriptional activity (28) . In the absence of transfected HNF-1␣, transactivation of the wild-type (Ϫ611/ϩ87)hMTP promoter and its P-DR1 or D-DR1 mutants by HNF-4␣ (C179W) was reduced by 2-to 5-fold compared with wildtype HNF-4␣ (Fig. 7) , indicating that ligand-dependent domains of HNF-4␣ were involved in transactivating the (Ϫ611/ϩ87)hMTP promoter. Furthermore, HNF-4(C179W) synergism with HNF-1␣ was reduced by 40-45% in the contexts of the wild-type, P-mut, and D-mut (Ϫ611/ϩ87) hMTP promoters compared with HNF-4␣(WT)/HNF1␣ (Fig. 7) , indicating that ligand-dependent domains of HNF-4␣ could be involved as well in synergizing hMTP transcription by HNF-4␣/HNF-1␣.
The putative role played by the ligand-independent activation function 1 (AF-1) domain of HNF-4␣ (42) (43) (44) in hMTP transactivation by HNF-4␣ and in synergizing the activity of HNF-1␣ was evaluated in HeLa cells transfected with wild-type HNF-4␣ or the HNF-4␣ (Y6D,Y14D,F19D ) mutant consisting of mutations previously reported to abort AF-1-mediated transcriptional activity of HNF-4␣ (42, 44) . In the absence of transfected HNF-1␣, transactivation of the wild-type (Ϫ611/ϩ87)hMTP gene promoter or its P-DR1 and D-DR1 mutants by HNF-4␣(Y6D,Y14D, F19D) was similar to that of wild-type HNF-4␣ (Fig. 7) , indicating that the ligand-independent AF-1 domain of HNF-4␣ was not involved in transactivating the (Ϫ611/ ϩ87)hMTP promoter by HNF-4␣. However, HNF-4␣(Y6D, Y14D,F19D) synergism with HNF-1␣ was reduced by 2.5-to 4.5-fold in the context of the wild-type, P-mut, and D-mut (Ϫ611/ϩ87)hMTP promoters compared with wildtype HNF-4␣ synergism with HNF-1␣ (Fig. 7) , indicating that the ligand-independent AF-1 domain of HNF-4␣ was specifically involved in synergizing hMTP transcription by HNF-4␣/HNF-1␣.
Transcriptional specificity of P-DR1 and D-DR1
DR1 is shared by PPAR, HNF-4, RXR, and COUP isoforms, prompting our interest in evaluating the transcriptional specificity of P-DR1 and D-DR1 in the context of the (Ϫ611/ϩ87)hMTP and the truncated (Ϫ74/ϩ87)hMTP promoters in HepG2 cells. HNF-4␣ appeared to be the only DR1 transactivating factor of the wild-type (Ϫ611/ ϩ87)hMTP promoter, whereas PPAR␣ was marginally active and COUP-TFI and COUP-TFII were strongly inhibitory (Fig. 8A) . In contrast to wild-type (Ϫ611/ϩ87)hMTP, (Ϫ611/ϩ87)hMTP(P-mut) and (Ϫ611/ϩ87)hMTP(D-mut) were transactivated by HNF-4␣ but not inhibited by COUP-TFI or COUP-TFII (Fig. 8B, C) . Furthermore, P-DR1 was robustly activated by COUP-TFI or COUP-TFII in the context of the truncated (Ϫ74/ϩ87)hMTP promoter (Fig.  8D) . Hence, the promoter activities of P-DR1 and D-DR1 acting in concert appear to be positively and negatively dominated by HNF-4␣ and COUP, respectively. Transactivation by HNF-4␣ is evident in the context of P-DR1 and D-DR1 acting in concert as well as when acting individually in the context of the P-mut or D-mut mutant of (Ϫ611/ϩ87)hMTP or the truncated (Ϫ74/ϩ87)hMTP promoters. In contrast, transsuppression by COUP requires P-DR1 and D-DR1 concerted activity, whereas COUP acts as a transactivator (45) rather than a suppressor in the context of the DR1 enhancers acting individually .
Suppression by COUP as a result of specifically antagonizing HNF-4␣-mediated transactivation was further verified in HeLa cells overexpressing HNF-4␣. As shown in Fig. 9 , COUP-TFII suppressed the transcriptional activity of HNF-4␣, both in the absence of added HNF-1␣ and in terms of HNF-4␣/HNF-1␣ synergism.
Suppression of hMTP expression and promoter activity by HNF-4␣ ligand antagonists
HNF-4␣ ligand agonists (e.g., fatty acids of C14-C16) have been repeatedly reported to induce VLDL production and hyperlipidemia ascribed to stabilizing nascent apoB and promoting its lipidation with hepatic TGs. In contrast, HNF-4␣ ligand antagonists [e.g., (n-3)PUFAs, fibrates, Medica analogs] induce hypolipidemia ascribed to the suppression of VLDL production (30, 31) together with activation of its plasma clearance (30, 33) . The putative role played by direct inhibition of hMTP transcription in the hypolipidemic activity induced by HNF-4␣ ligand antagonists was evaluated here by analyzing the effect of Medica analogs in suppressing hMTP expression and its promoter activity. hMTP expression in HepG2 cells was robustly inhibited by ␤,␤-tetramethyl-hexadecanedioic acid (Medica 16) or ␤,␤-tetramethyl-octadecanedioic acid (Fig.  10A) but not by the structurally related ␣,␣Ј-tetrachlorotetradecanedioic acid (Cl-DICA) (29) , which fails to suppress HNF-4␣ activity as a result of its nonavailability for ATP-dependent CoA-thioesterification (29) . Suppression of hMTP expression by Medica 16 but not by Cl-DICA, was similar to that of apoA-I and apoC-III, serving as a positive control for HNF-4␣-responsive genes engaged in lipoprotein metabolism (Fig. 10A) . hMTP suppression by Medica 16 was further verified in the context of the (Ϫ611/ϩ87) (Fig. 10C) . Medica 16 suppressed hMTP transactivation by HNF-4␣, both in the absence of HNF-1␣ and in the presence of HNF-4␣/HNF-1␣. Hence, HNF-4␣ ligand antagonists may specifically and directly inhibit hMTP promoter activity, which suppresses hMTP expression. Direct inhibition of hMTP promoter activity by HNF-4␣ ligand antagonists may offer a molecular basis for their hypolipidemic activity.
DISCUSSION
Endogenous HNF-4␣ was shown here by CHIP analysis to associate in vivo with the 5Ј-flanking proximal promoter of the liver hMTP gene. Furthermore, the hMTP gene promoter was shown in HepG2 cells to be transactivated or transsuppressed by overexpressed HNF-4␣ or dominant negative HNF-4␣, respectively, indicating that liver hMTP transcription was limited but not saturated by endogenous HNF-4␣. Also, the hMTP proximal promoter consists of distal (Ϫ83/Ϫ70)hMTP and proximal (Ϫ50/ Ϫ38)hMTP DR1 elements that bind HNF-4␣. Each of the two DR1 elements was required for HNF-4␣-dependent transactivation of the hMTP gene promoter, whereas the doubly DR1-mutated promoter was essentially inactive. Hence, the two DR1 elements of the hMTP promoter were complementary in transactivating hMTP by HNF-4␣. These findings corroborate the previously reported robust suppression of MTP in liver HNF-4␣ knockouts (46) and may further indicate that HNF-4␣ is directly required for hMTP promoter activity.
Transactivation of the hMTP gene promoter by HNF-4␣ is mediated by both HNF-4␣ domains engaged in liganddependent transactivation and by HNF-4␣/HNF-1␣ synergism. The role played by HNF-4␣ domains engaged in ligand-dependent transactivation and recruitment of transcriptional coactivators was demonstrated by the hampered transcriptional activity of the HNF-4␣(C179W) mutant (28) compared with wild-type HNF-4␣. HNF-4␣ synergism with HNF-1␣ was demonstrated by the robust transactivation of hMTP by the HNF-4␣/HNF-1␣ couple under conditions of marginal transcriptional activity of HNF-1␣ per se. The characteristics of hMTP transactivation by HNF-4␣/HNF-1␣ are worth noting. First, the HNF-1␣ response element of the hMTP promoter was previously reported to be required for transactivation by HNF-1␣, as verified by the 95% decrease in the activity of the hMTP promoter mutated in its HNF-1␣ element (11) . The lack of HNF-4␣/HNF-1␣ synergism in the context of the truncated (Ϫ74/ϩ87)hMTP promoter, devoid of an HNF-1␣ response element, may indicate that docking of HNF-1␣ to its response element may be required as well for HNF-4␣/ HNF-1␣ synergism. HNF-4␣/HNF-1␣ synergism mediated by docking of both to the hMTP promoter is in agreement with the HNF-4␣/HNF-1␣ synergism previously reported in the context of the ␣ 1 -antitrypsin gene promoter (41) . It is worth noting that the previously reported inhibition of HNF-4␣ transcriptional activity by its interaction with HNF-1␣ concerns a promoter devoid of an HNF-1␣ response element (23) and therefore is not applicable to the hMTP promoter. Second, the synergistic HNF-4␣/HNF-1␣ interaction was mediated by HNF-4␣ binding to either one of the two DR1 elements of the hMTP proximal promoter. Third, transactivation by HNF-4␣ in the absence of HNF-1␣ remained unaffected by mutating the HNF-4␣ AF-1 domain, whereas the AF-1 domain was specifically involved in HNF-4␣/HNF-1␣ synergism, as verified by the decreased activity of HNF-4␣(Y6D,Y14D,F19D)/HNF-1␣. Hence, transactivation by HNF-4␣/HNF-1␣ is mediated by distinct HNF-4␣ domains and distinct DR1 elements of the hMTP promoter.
Similarly to the COUP antagonism of HNF-4␣ transactivation of the apoC-III, apoB, and apoA-II gene promoters (19, 20) , liver hMTP transcription was shown here to be robustly inhibited by overexpressed COUP. Because COUP may compete with HNF-4␣ for binding to DR1 elements, liver hMTP suppression by COUP may be ascribed to COUP displacement of the endogenous (Fig. 8) or trans- 
